OncoDNA Announces the Operational Launch of its OncoDEEP® Kit for Comprehensive Genomic Profiling of Solid Tumors

The OncoDEEP Kit integrates both reagents and quality control reporting for sequencing over 600 cancer genes and relevant biomarkers, together with OncoDNA’s data analysis and clinical interpretation tools for the rapid analysis and reporting of a patient’s tumor molecular profile. The OncoDEEP Kit has been developed by expert oncologists to contain the most complete panel of biomarkers known to be associated with cancer therapies. The kit incorporates Twist Bioscience’s enrichment and library preparation solutions and has been optimized for the reliable analysis of somatic variants and translocations. It has been available for early access since February 2022 and is now commercially available.

OncoDNA’s extensive experience in genomic profiling for precision oncology has been translated into a relevant gene panel and associated interpretation tools. The panel allows for the measurement of complex genomic signatures that act as predictive biomarkers for cancer therapy, such as homologous recombination deficiency (HRD), tumor mutational burden (TMB), microsatellite instability (MSI) and loss of heterozygosity (LOH).

OncoDNA’s aim is to make genomic profiling more widely available to cancer patients around the world. The solution can benefit the complete range of customer profiles: experienced users have access to the full analytical details, and those with limited bioinformatics knowledge can rely on the robust and user friendly software tools. All users can extract and tailor patient-specific clinical interpretation reports online thanks to the secure, cloud-based software tools and proprietary biomarker database. This database is revised daily, and currently includes more than 4,500,000 genetic variants, 1,150 cancer drugs, and 7,000 clinical trials.

“We are excited to transfer our knowledge and facilitate the routine use of comprehensive biomarker testing in other laboratories,” stated Jean-Pol Detiffe, Chief Strategy and Innovation Officer and Founder of OncoDNA. “While OncoDEEP has been our flagship biomarker test since 2014, we see more and more laboratories adopting NGS technology and becoming interested in utilizing our test in-house. We believe that this version of OncoDEEP will be a very attractive proposition for numerous hospitals. With the associated bioinformatics software suite, the OncoDEEP Kit will enable them to identify a broader set of treatment options for their patients with one single test, while saving on the cost and burden of outsourcing to us.”

ABOUT ONCODNA

OncoDNA is a genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic diseases. The company helps clinicians, academic researchers and biopharma companies to outsmart molecular complexity with the mission of delivering the promise of precision medicine. The company not only provides clinical guidance for the treatment and real-time monitoring of late stage cancer patients, but also supports research and drug development in cancer and genetic diseases. Since the early days in 2012, OncoDNA has grown into a corporate group of companies with world-renowned expertise. The Group offers a unique portfolio that combines NGS services, biomarker testing, data analysis software and clinical decision support tools. OncoDNA is headquartered in Belgium, and its entities – BioSequence and IntegraGen – are based in Spain and France, respectively. The Group employs over 100 people across 9 countries, works with an international network of 35 distributors, and collaborates with both European-based and US-based subcontracted and accredited laboratories.